Overview of Нимулид

Quick Facts

Property	Description
Active ingredient	Nimesulide
Form	Tablets, capsules, granules for oral suspension, gel
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use	Symptomatic relief of pain, inflammation, and fever
Origin	Synthetic, Sulfonanilide derivative

Нимулид: Classification and Origin

Нимулид is the commercial name for a medication whose single active component is Nimesulide, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This is a synthetic compound, chemically identified as a sulfonanilide derivative, with the molecular formula C13H12N2O5S. The drug is characterized by its mechanism as a relatively selective Cyclooxygenase-2 (COX-2) inhibitor, separating its primary action from that of non-selective agents. It provides anti-inflammatory effects with a relatively rapid onset of action.

Composition and Available Drug Forms

The medicine is supplied as a single-component product (monotherapy), ensuring the therapeutic effect is derived exclusively from the Nimesulide compound. Нимулид is available in several dosage forms, facilitating different routes of administration. These preparations include solid oral forms such as tablets and capsules, powder-based granules for oral suspension, and a gel formulation intended for topical application. The inclusion of various physical forms, such as oral suspension granules, allows for patient flexibility in administration beyond traditional tablets.

General Purpose and Physiological Action

The overall general purpose of Нимулид is to provide symptomatic relief through a core triple action: an anti-inflammatory effect, an analgesic (pain relief) effect, and an antipyretic (fever reduction) effect. This action occurs through the modulation of the biosynthesis of inflammatory mediators, such as prostaglandins, which is a mechanism characteristic of the NSAID class. The application of Nimesulide is intended for the treatment of acute pain and primary dysmenorrhoea. The drug functions to alleviate the discomfort associated with acute symptoms, such as the transient pain that accompanies common musculoskeletal strain.

What side effects are possible with Нимулид?

Possible side effects and safety information

Nimesulide (Нимулид) is associated with an official safety profile structured by system-organ classes and frequency categories, as documented in governmental regulatory sources. Like other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), its adverse reactions are classified as Uncommon, Rare, or Very Rare.

System-Organ Classification and Frequency

The documented adverse reactions primarily affect the Hepato-Biliary System (liver), the Gastrointestinal System (stomach and intestines), and the Skin and Subcutaneous Tissue (dermatological effects).

Uncommon effects include gastrointestinal reactions (such as nausea, vomiting, or diarrhea) and blood pressure fluctuations.
Rare effects involve hypersensitivity reactions, headache, or visual disturbances.

Serious Adverse Reactions

The regulatory label highlights the potential for serious, though Very Rare, adverse events. These include life-threatening complications such as Fulminant hepatic failure (with fatal cases reported), Gastrointestinal bleeding, ulceration, or perforation, and severe skin reactions like Stevens-Johnson syndrome.

Regulatory Safety Restrictions

Official regulatory documents enforce strict limitations on Nimesulide's systemic use:

Duration: The maximum course of treatment is officially limited to 15 days to reduce the risk of liver damage.
Contraindications: Use is strictly contraindicated in patients with severe hepatic or renal impairment, active gastrointestinal bleeding or ulceration, severe heart failure, and during the third trimester of pregnancy.
Population: The drug is contraindicated for use in children under 12 years of age. Older adults are noted to be particularly susceptible to the gastrointestinal and renal adverse effects associated with NSAIDs.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Clinical Manifestations

Regulatory documents state that an acute overdose of Nimesulide may present with recognized clinical signs, including gastrointestinal disturbances such as nausea, vomiting, and epigastric pain. Systemic effects like lethargy and drowsiness are also documented presentations. Furthermore, signs compatible with severe hepatic injury, such as anorexia, fatigue, or dark urine, are indications that require immediate medical assessment, even if an overdose is only suspected.

Severe Complications and Emergency Action

Overdose carries the potential for severe and life-threatening outcomes, including acute renal failure, hepatic failure (which can rarely be fatal), and serious gastrointestinal complications such as bleeding or perforation. Coma and severe hypersensitivity reactions (anaphylactoid reactions) are also documented. Due to the risk of these severe systemic effects, the regulator-mandated instruction is to seek immediate medical attention for any suspected overdose. Urgent medical care is required immediately upon suspicion or the development of any severe manifestations.

Management and Monitoring Requirements

Management of overdose is defined as strictly symptomatic and supportive treatment, as no specific antidote is known for Nimesulide. Officially described procedural interventions include the possible use of gastric lavage or administration of activated charcoal if presented within a few hours of ingestion. Hospital observation is required, with mandatory monitoring of both renal function and hepatic function. Official labeling notes that the elderly population is particularly susceptible to the severe adverse effects involving renal and hepatic systems following an overdose.

Therapeutic Uses of Нимулид

The medication is used for the management of certain symptoms.

Therapeutic Scope and Key Indications

The medication is commonly used for managing symptoms related to inflammatory or irritative states that manifest as acute pain. Its application is relevant across conditions presenting with disruptive symptom manifestations, and is applied in clinical settings that involve acute or unstable symptom patterns for acute musculoskeletal discomfort (such as pain from sprains and strains), and managing the acute, episodic pain of primary dysmenorrhoea (menstrual cramps). The medication also plays a role in managing symptoms related to systemic imbalance, specifically by assisting with elevated body temperature when fever is present alongside pain.

This is relevant when supportive symptom management is appropriate. The medication helps manage the acute discomfort that interferes with routine activities. This symptomatic support assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Acute Discomfort	Symptom Domain	Target Clinical Context
Acute Pain	Musculoskeletal trauma (sprains, strains), joint flare-ups	Contributes to improved day-to-day comfort
Episodic Pain	Primary dysmenorrhoea (menstrual cramps)	Helps patients cope more steadily with symptom fluctuations
Fever	Pain and elevated temperature in acute inflammatory states	Supports general well-being during symptomatic phases

Regulatory References

European Medicines Agency (EMA) Scientific Conclusions

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

The medicine is permitted for use in adults and adolescents aged 12 years and older. Patients with mild to moderate renal impairment (creatinine clearance 30-80 ml/min) are generally eligible, and dosage adjustments are not typically required for older adults.

Populations for whom use is contraindicated:

Use is strictly prohibited for children below 12 years of age and for individuals with a known history of hepatotoxic reactions to Nimesulide. Absolute contraindications also include hepatic impairment (liver dysfunction) of any severity, severe renal impairment (creatinine clearance <30 ml/min), severe heart failure, and the presence of active gastrointestinal ulcer or bleeding. The medicine is also contraindicated in patients with severe coagulation disorders and those with a history of recurrent ulceration.

Age-related eligibility rules:

Use is contraindicated for individuals below 12 years. It is permitted for individuals 12 years and older.

Pregnancy and lactation eligibility status (if explicitly documented):

Use is contraindicated during both pregnancy and lactation (breastfeeding).

Eligibility-related restrictions:

This medication is officially designated as a second-line treatment. Use is restricted to a maximum treatment duration of 15 days. Concomitant exposure to other potentially hepatotoxic substances is also contraindicated.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): The most frequent and severe classification is Contraindicated.

Eligibility-context constraints (as defined in official documents): Treatment is limited to a second-line status and a 15-day maximum duration.

Connection to the overall eligibility profile: The regulatory profile strictly defines who can and cannot use the medicine by reserving use for specific adult and adolescent populations who lack any co-existing conditions that affect the liver, kidneys, or gastrointestinal system. This structure ensures that only low-risk individuals are eligible for limited, short-term treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the co-administration of Nimesulide (Нимулид) with other substances, primarily due to the risk of altering drug exposure or causing additive adverse effects.

Contraindicated Combinations and Restrictions

Nimesulide must not be combined with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including salicylates (e.g., Aspirin), due to the heightened risk of gastrointestinal and other adverse events. Co-administration with other potentially hepatotoxic substances (e.g., Paracetamol) is restricted due to the additive risk of liver toxicity. Alcohol abuse must also be avoided during treatment.

Clinically Significant Drug Interactions

The co-administration of Nimesulide with Anticoagulants (e.g., Warfarin) increases the risk and severity of bleeding and hemorrhage, requiring close clinical monitoring of coagulation status. Nimesulide may reduce the antihypertensive effect of ACE-Inhibitors and Angiotensin II Antagonists.

Exposure-Modifying Interactions

Nimesulide may increase the plasma concentrations of certain co-administered drugs. This is documented for substances such as Lithium, Methotrexate, and Digoxin, often resulting from reduced renal clearance or inhibition of the CYP2C9 enzyme activity, which may increase the exposure of drugs metabolized by this pathway. Additionally, Nimesulide may decrease the oral bioavailability and natriuretic effect of Furosemide.

Mechanism of Action

Нимулид (Nimesulide) functions primarily by modulating the lipid-based signaling cascade involved in inflammation. Its main action is the selective inhibition of cyclooxygenase-2 (COX-2), an inducible enzyme that is highly expressed during cellular response to damage.

In the cytosol, COX-2 catalyzes the conversion of arachidonic acid—a phospholipid-derived substrate—into prostaglandin H2 (PGH2). This step is integral to the synthesis of various pro-inflammatory eicosanoids, including specific prostaglandins that modulate cellular processes. By binding to the active site of COX-2, Nimesulide reduces the catalytic activity of the enzyme, thereby resulting in a diminished local synthesis of these potent lipid mediators.

Beyond COX-2 modulation, the compound also interferes with other factors, including the partial suppression of certain matrix metalloproteinases (MMPs) and the inhibition of platelet-activating factor (PAF) synthesis. This multi-faceted molecular interference contributes to the overall systemic anti-inflammatory physiological modulation achieved by the drug, without making reference to any clinical outcome.

Dosage and Administration Information

How to Use Нимулид: General Administration Guidelines

This section describes the parameters for using Нимулид (Nimesulide) as established in standard medical documentation.

Approved Forms and Dosing

Нимулид is available in forms that facilitate different routes of administration, including solid oral forms (tablets, capsules) and granules for suspension for systemic use, as well as a topical gel for local application.

The standard oral dose for adults is 100 mg per dose, taken twice daily (bid). This establishes the maximum recommended daily intake at 200 mg. The medication is intended to be used at the minimum effective dose for the shortest possible duration of time to meet treatment needs.

Administration Detail	Description
Route of Administration	Oral (Systemic), Topical (Local)
Standard Single Dose	100 mg
Maximum Daily Dose	200 mg
Frequency	Twice daily (bid)
Relation to Meals	Oral forms are taken after a meal.

Duration and Population Rules

The treatment course for systemic Нимулид is specified not to exceed 15 days for any single course of use. This time constraint defines the medication's application as limited to acute, short-term symptomatic management.

Dosage Adjustments for Specific Populations:

No dosage adjustment is required for older adults or for adolescents aged 12 to 18 years. Likewise, no adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance 30-80 ml/min). Use in children under 12 years is not recommended.

Recent Clinical Evidence

Research evidence / Overview of Studies for Нимулид (Nimesulide)

Evidence for Use in Acute Pain States

The research base for Нимулид in the acute pain settings that have been explored consists mainly of randomized controlled trials (RCTs). These studies are used in research exploring how symptoms change over time. Researchers designed these trials to examine short-term or episodic symptom patterns, focusing on populations of adults and adolescents (aged 12 years and older) experiencing acute, self-limiting pain, such as that associated with musculoskeletal discomfort or post-operative conditions.

Studies monitored patient-reported outcomes describing perceived discomfort. Specifically, research examined measures of pain intensity over brief observation intervals, as well as the time measured for the onset of change. The findings describe patterns observed in the studies, where the measured outcomes related to physical discomfort evolved in the observed populations compared to placebo and sometimes compared to active comparators.

Evidence for Use in Primary Dysmenorrhoea

Research has examined Nimesulide in the context of primary dysmenorrhoea (menstrual cramps), a condition characterized by fluctuating or episodic manifestations. The evidence in this area is also derived from short-term RCTs. These studies were applied in research contexts involving fluctuating or unstable symptoms where researchers were interested in outcomes capturing phases of heightened symptom activity.

Trials monitored patient-reported outcomes describing perceived discomfort during periods of increased symptom activity. Studies monitored pain intensity and sometimes examined physiological outcomes related to inflammation. Findings describe patterns observed in the studies related to these outcomes, which contribute to understanding how patients reported their experience during the treated cycle.

Duration of Evidence: Short-Term Focus and Follow-up

The overall evidence base for Нимулид consists mainly of short-term study designs, which aligns directly with the acute nature of its approved uses. Research was conducted during periods of increased symptom activity and observed responses over defined time intervals that rarely exceed two weeks. This means that the results apply only to the populations studied under these specific, restricted timeframes.

Duration limits on continuous use (maximum 15 days) reflect the design and focus of the research. This is consistent with the current evidence landscape, where long-term effects are not fully established, and studies have not provided information on whether patients experience consistent outcomes if the medication were to be used beyond its acute contexts.

Frequently Asked Questions (FAQ)

Common questions about Нимулид (FAQ)

Q: How quickly can I expect to feel relief after taking Нимулид?

Studies and official information indicate that nimesulide is characterized by a relatively rapid onset of action for pain relief. This feature is often noted in research examining its use for acute pain conditions.

Q: How long does the effect of one dose of Нимулид last?

Official dosing instructions recommend taking the medication twice daily. This frequency is consistent with the established interval between doses.

Q: What are the most commonly reported side effects of Нимулид?

According to official safety documents, the commonly reported undesirable effects (occurring in less than 1 in 10 patients) typically affect the gastrointestinal system. These include symptoms such as diarrhea, nausea, and vomiting.

Q: Is it normal to feel a stomach upset after taking Нимулид?

Gastrointestinal reactions like diarrhea, nausea, or vomiting are documented as common adverse reactions in the official safety profile. This is why official guidance advises taking the drug after a meal.

Q: Can I take Нимулид if I am taking blood pressure medicine?

Official documents indicate that nimesulide may reduce the blood pressure-lowering effects of certain types of antihypertensive drugs. Specifically, this interaction is noted with ACE-Inhibitors and Angiotensin II Antagonists.

Q: Why is Нимулид restricted or banned in some countries?

Regulatory restrictions, such as limiting use to a maximum of 15 days, were implemented following official reviews that identified a need to minimize the potential for developing serious liver problems. Authorities restrict its use to keep these risks to a minimum.

Q: Is it true that Нимулид can affect the kidneys?

Official regulatory text notes that caution is required in patients who already have kidney impairment because nimesulide may result in a deterioration of kidney function. Severe kidney impairment is listed as a specific contraindication for use.

Q: What are the signs of an allergic reaction to Нимулид?

Hypersensitivity reactions are listed as rare adverse effects in the safety profile. Documented reactions involving the skin include rash and itching, and in very rare instances, there have been reports of severe reactions involving swelling of the face, tongue, or throat.

Q: Is the side effect profile of topical Нимулид (gel) different from the oral form (tablets)?

Systemic exposure from the gel is documented as very low compared to oral forms. The risk of systemic adverse reactions, such as liver or gastrointestinal effects, is only noted as possible with long-term use or application to large areas of skin.

Q: What is the main difference between Нимулид and regular pain relievers?

Нимулид is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) that functions as a relatively selective inhibitor of cyclooxygenase-2 (COX-2). The drug is characterized by this action, while other NSAIDs may target both COX-1 and COX-2.

Q: Is Нимулид a type of antibiotic?

No, Нимулид is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its primary actions are to provide pain relief, reduce inflammation, and lower fever, not to treat bacterial infections.

Q: Can Нимулид be used for chronic pain?

Official regulatory decisions restrict the use of systemic Нимулид to the treatment of acute pain and primary dysmenorrhoea (menstrual cramps). It is no longer recommended for treating chronic conditions like painful osteoarthritis.

Q: Can I use other pain creams or gels while using Нимулид gel?

The systemic drug should not be combined with other oral NSAIDs. For the gel, official documents advise that caution is required, as the possibility of developing hypersensitivity in the course of therapy with other topical NSAIDs cannot be excluded.

Q: What is the connection between Нимулид and cardiovascular risk?

Severe heart failure is listed as a contraindication for the use of systemic nimesulide. Furthermore, patients with heart failure or uncontrolled hypertension require appropriate monitoring, as fluid retention has been reported with NSAID therapy.

Q: Can I take Нимулид on an empty stomach?

Official administration instructions mandate that oral forms of Нимулид must be taken after a meal. This guidance is generally intended to help minimize the potential for gastrointestinal upset or irritation.

Q: Can I use Нимулид for headache?

The official indication for the systemic use of Нимулид is restricted to the treatment of acute pain and primary dysmenorrhoea. Health authorities recommend its use only for these specified conditions.

Q: What is the mechanism by which Нимулид is thought to cause liver problems?

Nimesulide is metabolized in the liver via cytochrome P450 enzymes. Scientific reviews suggest that cellular toxicity may be related to this metabolic pathway and the generation of oxidative stress within the liver cells, leading to potential damage.

Q: Does Нимулид affect blood sugar levels?

Formal studies on patients with diabetes who were taking blood sugar-lowering medication found that the drug did not influence either fasting blood sugar or glucose tolerance. It is not generally associated with changes in blood sugar control.

Q: Why is Нимулид sometimes categorized as a 'last-resort' treatment?

Official regulatory decisions restrict systemic nimesulide to second-line treatment status. This means its use is reserved for situations where at least one other medicinal product has failed to provide relief for acute pain or primary dysmenorrhoea.

Q: Can taking Нимулид cause drowsiness or dizziness?

Dizziness and somnolence (drowsiness) are documented as potential side effects in the official safety profile. The product label includes a warning that patients who experience these effects should refrain from driving or operating machinery.

Q: Can I use Нимулид for toothache?

The official indication for the systemic use of Нимулид is restricted to the treatment of acute pain and primary dysmenorrhoea. Treatment must remain within these restricted categories as defined by regulatory authorities.

Q: How long does Нимулид stay in the body after the last dose?

Pharmacokinetic data reports the elimination half-life of nimesulide as ranging from approximately 2 to 5 hours. The half-life refers to the time it takes for the concentration of the drug in the body to decrease by half.

Q: Can Нимулид be used for muscle soreness after exercise?

The official indication for the systemic use of Нимулид is restricted to the treatment of acute pain and primary dysmenorrhoea. This means its use is authorized only for temporary, acute pain that fits within these restricted indications.

How should Нимулид be stored and disposed of?

How to Store and Dispose of Nimulid (Nimesulide)

The storage and handling of Nimulid must adhere strictly to the conditions defined in the official regulatory labeling to ensure product integrity.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30 C
Protection	Protect the medicine from moisture
Container	Store the medicinal product in the original container
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Any unused Nimulid or waste material must be disposed of in accordance with local regulatory requirements. Medicines should not be disposed of via household waste or wastewater, as specified in standard environmental guidelines for pharmaceutical products. Following these official rules ensures the correct and safe handling of the product.

Нимулид